Natixis’s Xenon Pharmaceuticals XENE Stock Holding History

Natixis’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$123K	Buy	+2,037	New	+$113K	﹤0.01%	981
2024 Q1	–	Sell	-7,000	Closed	-$322K	–	1255
2023 Q4	$322K	Sell	7,000 -3,000	-30%	-$106K	﹤0.01%	663
2023 Q3	$342K	Buy	10,000 +3,000	+43%	+$112K	﹤0.01%	658
2023 Q2	$270K	Buy	+7,000	New	+$278K	﹤0.01%	709

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Natixis's XENE Position: Q2 2026 in Review

Natixis opened a new position in Xenon Pharmaceuticals (XENE) in Q2 2026: 2,037 shares worth $123K. The stake represents ﹤0.01% of the portfolio and ranks #981 among its holdings. This is a return to the name: Natixis previously reported a position in XENE as recently as Q4 2023.

Natixis first reported a position in XENE in Q2 2023 and has held it in 4 quarters since. The position peaked at $342K in Q3 2023. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

Natixis held 2,037 shares of Xenon Pharmaceuticals worth $123K as of Q2 2026.
Xenon Pharmaceuticals was a new Natixis position in Q2 2026.
Xenon Pharmaceuticals made up ﹤0.01% of Natixis's portfolio in Q2 2026, its #981 holding.
Natixis first reported a position in Xenon Pharmaceuticals in Q2 2023 and has held it in 4 quarters since.
Natixis's Xenon Pharmaceuticals position peaked at $342K in Q3 2023.
315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Natixis's 13F filing for Q2 2026, filed 13 Aug 2026.